Capivasertib | pan-AKT inhibitor

CAS:
 1143532-39-1
Catalog Number:
 10-4383

Available Options

Size:PriceQuantity 
5 mg$60.00
25 mg$195.00
Request Quote / Bulk / Custom Size
Product Inquiry

Capivasertib (1143532-39-1) is a potent ATP-competitive pan-Akt inhibitor (IC50s: Akt1 = 3 nM, Akt2 = 8 nM, Akt3 = 8 nM).1,2 It reduced tumor vascular density, decreased influx of myeloid cells, and reduced tumor regrowth in hepatocarcinoma models in conjunction with radiotherapy.3 Capivasertib significantly reduced cancer migration and invasion in a colorectal cancer model.4 It enhanced CAR-T cell activity in B cell lymphoma models.5 FDA approved for the treatment of HR+/HER2-negative breast cancer.

References/Citations:

  1. Addie et al. (2013), Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases; J. Med. Chem. 56 2059
  2. Davies et al. (2012), Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy with genetic background; Mol. Cancer Ther. 11 873
  3. Searle et al. (2017), Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment; EMBO Mol. Med. 9 1646
  4. Yang et al. (2025), Targeting the CCL28-STAT3-PLAC8 axis to suppress metastasis and remodel the tumor microenvironment in colorectal cancer; Front. Immunol. 16 1610540
  5. Hsieh et al. (2025), Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma; Mol. Ther. Methods Clin. Dev. 33 101421
1143532-39-1, AKT inhibitor, AZD-5363, AZD5363, AZD5363 supplier, Capivasertib, Capivasertib supplier, pan-AKT inhibitor
CAS:
1143532-39-1
Catalog Number:
10-4383
Activity:
pan-AKT inhibitor
Chemical Names:
4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
Alternate Name:
AZD5363
Molecular Weight:
428.92
Molecular Formula:

C21H25ClN6O2

Solubility:
Soluble in DMSO (>50 mg/ml)
Physical Properties:
White solid
Purity:

98% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Capivasertib (1143532-39-1) is a potent ATP-competitive pan-Akt inhibitor (IC50s: Akt1 = 3 nM, Akt2 = 8 nM, Akt3 = 8 nM).1,2 It reduced tumor vascular density, decreased influx of myeloid cells, and reduced tumor regrowth in hepatocarcinoma models in conjunction with radiotherapy.3 Capivasertib significantly reduced cancer migration and invasion in a colorectal cancer model.4 It enhanced CAR-T cell activity in B cell lymphoma models.5 FDA approved for the treatment of HR+/HER2-negative breast cancer.

References/Citations:

  1. Addie et al. (2013), Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases; J. Med. Chem. 56 2059
  2. Davies et al. (2012), Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy with genetic background; Mol. Cancer Ther. 11 873
  3. Searle et al. (2017), Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment; EMBO Mol. Med. 9 1646
  4. Yang et al. (2025), Targeting the CCL28-STAT3-PLAC8 axis to suppress metastasis and remodel the tumor microenvironment in colorectal cancer; Front. Immunol. 16 1610540
  5. Hsieh et al. (2025), Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma; Mol. Ther. Methods Clin. Dev. 33 101421

STEM CELL

BOGO